Krystal Biotech, Inc.
NASDAQ:KRYSBiotechnology
+$18.29 today
- Market cap
- $9.34B
- Beta
- 0.53
- P/E (TTM)
- 44.5
- EPS (TTM)
- $7.68
Volume 0.35M
Average 0.29M
KRYS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Krystal Biotech, Inc.NASDAQ: KRYS
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA growth accelerates
Q2 FY2026 EBITDA of $67.65M rose 40.0% year over year, ahead of the +22.1% change in trailing-twelve-month EBITDA. Sequentially, it rose 7.1% from the prior quarter.
Context
- EBITDA amounted to 50.4% of revenue in FY2025, up 12.5 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of $305.54M (+55.9%) for the fiscal year ending Dec 2026, a slowdown from the +78.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $67.65M+7.1% QoQ
- Last fiscal yearDec 2025
- $196.02M+78.3% YoY
- LTMJun 2026
- $220M+22.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +40.0% | +44.3% | +4.3 pp |
| 1 year | +78.3% | +55.9% | -22.5 pp |
| 3-year CAGR | — | +39.9% | — |
| 5-year CAGR | +44.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 196.02M USD
- Year-over-year change
- +78.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 196.02M | +78.3% |
| FY2024 | 2024-12-31 | 109.91M | +219.2% |
| FY2023 | 2023-12-31 | (92.22M) | +20.6% |
| FY2022 | 2022-12-31 | (116.14M) | -77.8% |
| FY2021 | 2021-12-31 | (65.31M) | — |
EBITDA vs competitors
How KRYS compares with its peers on the latest reported figures
- KRYS's LTM Jun 2026 EBITDA of $220M is the highest of the 6 companies compared; the peer median is -$187.06M.
- Its year-over-year change of +22.1% is the 3rd highest of 6, against a peer median of +21.0%.
- EBITDA amounts to 49.9% of revenue for KRYS, versus a peer median of 261.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $220M | +22.1% | — | 49.9% | |
| LTM Mar 2026 | $73.43M | +298.8% | — | 505.0% | |
| LTM Mar 2026 | -$95.72M | +32.5% | — | 120.0% | |
| LTM Mar 2026 | -$187.06M | +2.3% | — | — | |
| LTM Mar 2026 | -$194.47M | +21.0% | — | — | |
| LTM Mar 2026 | -$229.35M | -87.3% | — | 261.2% | |
| Peer median (excluding KRYS) | -$187.06M | +21.0% | — | 261.2% | |
Competitors are the stored peer set for KRYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 50.7M | 290.52M | 389.13M |
| Cost of Revenue | 0 | 0 | 3.09M | 20.06M | 28.77M |
| Gross Profit | 0 | 0 | 47.61M | 270.45M | 360.36M |
| Gross Margin | — | — | 93.9% | 93.1% | 92.6% |
| Research & Development | 27.88M | 42.46M | 46.43M | 53.57M | 58.05M |
| Selling, General & Admin | 40.39M | 77.74M | 98.4M | 113.69M | 146.74M |
| Operating Expenses | 68.28M | 145.2M | 157.33M | 204.76M | 199.06M |
| Depreciation & Amortization | 2.77M | 4.05M | 5.01M | 6.71M | 6.55M |
| EBITDA | (65.31M) | (116.14M) | (92.22M) | 109.91M | 196.02M |
| EBITDA Margin | — | — | -181.9% | 37.8% | 50.4% |
| Operating Income | (68.28M) | (145.2M) | (109.73M) | 65.7M | 161.3M |
| Operating Margin | — | — | -216.4% | 22.6% | 41.5% |
| Interest Income | 197K | 5.22M | 22.62M | 29.66M | 28.18M |
| Interest Expense | 1.49M | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1.3M) | 5.22M | 122.62M | 29.66M | 28.18M |
| Income Before Tax | (69.57M) | (139.98M) | 12.9M | 95.36M | 189.47M |
| Pre-Tax Margin | — | — | 25.4% | 32.8% | 48.7% |
| Income Tax Expense | 0 | 0 | 1.97M | 6.2M | (15.36M) |
| Net Income | (69.57M) | (139.98M) | 10.93M | 89.16M | 204.83M |
| Net Margin | — | — | 21.6% | 30.7% | 52.6% |
| EPS (Basic) | (3.13) | (5.49) | 0.40 | 3.12 | 7.08 |
| EPS (Diluted) | (3.13) | (5.49) | 0.39 | 3.00 | 6.84 |
| Weighted Avg Shares | 22.2M | 25.49M | 27.15M | 28.59M | 28.94M |
| Weighted Avg Shares (Diluted) | 22.2M | 25.49M | 27.75M | 29.74M | 29.95M |
Krystal Biotech, Inc.
NASDAQ:KRYS
Intrinsic Alpha fair value
Locked
Current Price
$315.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.